Dongwha Pharm and Korea Pfizer Renew Sales Contract for Antidepressant 'Pristiq SR Tablets'

Pfizer antidepressant Pristiq ER tablets.

[Asia Economy Reporter Lee Gwan-joo] Dongwha Pharm announced on the 7th that it has extended the co-promotion contract for 'Pristiq Extended-Release Tablets,' a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant from Pfizer Korea, and signed a sales and distribution contract covering all domestic channels.

Since 2018, Dongwha Pharm and Pfizer Korea have maintained a cooperative relationship through a co-promotion contract for the sales and distribution of Pristiq Extended-Release Tablets to hospitals and clinics.

Under this agreement, Pfizer Korea will continue to handle the import and marketing of the product, while Dongwha Pharm will expand the scope of its co-promotion from hospitals and clinics to sales and distribution across all domestic channels through this contract.

Yoo Jun-ha, CEO of Dongwha Pharm, said, "The renewal of the contract was possible based on the trust built between the two companies over the past seven years. Dongwha Pharm will further strengthen its expertise in the CNS field to provide better treatment opportunities to customers."

Jung Jang-hwan, Executive Director and Lead of the Internal Medicine Business Unit at Pfizer Korea, stated, "We hope that through this agreement with Dongwha Pharm, Pfizer's innovative treatment options will be made available to more patients suffering from major depressive disorder."

Pristiq Extended-Release Tablets are antidepressants made from desvenlafaxine, the major active metabolite of venlafaxine. As an SNRI antidepressant, it has the advantage of a low risk of drug interactions because it is neither metabolized nor inhibited by CYP2D6.

This content was produced with the assistance of AI translation services.